Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1968P - The clinical effect of concurrent oncogenic gene mutations in BRAF p.(V600E)-mutated NSCLC treated with dabrafenib and trametinib

Date

17 Sep 2020

Session

E-Poster Display

Topics

Translational Research

Tumour Site

Presenters

Pei Meng

Citation

Annals of Oncology (2020) 31 (suppl_4): S1034-S1051. 10.1016/annonc/annonc294

Authors

P. Meng1, B. Koopman1, K. Kok2, A. ter Elst1, E. Schuuring1, L. C. van Kempen1, W. Timens1, T..J.N. Hiltermann3, H. J.M. Groen3, A. van den Berg1, A. J. van der Wekken3

Author affiliations

  • 1 Pathology Dept, University of Groningen, University Medical Center Groningen (UMCG), 9700 RB - Groningen/NL
  • 2 Genetics Dept, University of Groningen, University Medical Center Groningen (UMCG), 9700 RB - Groningen/NL
  • 3 Pulmonary Diseases Dept, University of Groningen, University Medical Center Groningen (UMCG), 9700 RB - Groningen/NL

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1968P

Background

Combined dabrafenib and trametinib treatment of advanced non-small cell lung cancer (NSCLC) patients harboring BRAF p.(V600E) mutations results in an overall response rate of about 60%. However, the duration of response is limited and variable. It is still unknown whether co-occurring gene mutations confer resistance to the dual BRAF and MEK inhibition therapy.

Methods

Samples from 36 advanced NSCLC patients before dabrafenib and trametinib treatment were included. The most common clinically relevant hotspot mutations in lung cancer were tested by targeted next generation sequencing for treatment decision making. Progression-free survival (PFS) data were collected from the clinical records.

Results

A BRAF p.(V600E) was identified in 35 patients and a p.(V600_K601delinsE) was observed in one patient. Concurrent oncogenic mutations were observed in 8 of the 36 patients, involving the mTOR pathway (PIK3CA and AKT1) in 4 patients, MAPK/ERK pathway (BRAF non-V600E), KIT in one patient, IDH1 in 2 patients, and GNAS in one patient. Patients with and without concurrent mutations had a PFS of 20.3 and 10.2 months, respectively. Log-rank analysis showed no significant difference, P=0.58. The patient with a BRAF p.(V600_K601delinsE) responded to the treatment and had a PFS of 5 months. The patient that had a concurrent BRAF p.(G466V) and KIT p.(K509Q) mutations had a stable disease for only 3 months. Patients with a concurrent PIK3CA p.(G1049R) or AKT1 p.(E17K) mutation had a relatively short PFS of 4 and 3 months, respectively. Two patients with a concurrent PIK3CA p.(H1047R) mutation had an ongoing response of 54 and 57 months. The two patients with a concurrent IDH1 p.(R132C) mutation had a complete response with a PFS of 32 months and an ongoing response of 12 months. The patient with a GNAS p.(R201C) had a PFS of 8 months.

Conclusions

There was no difference for PFS between patients with and without concurrent mutations as assessed by our diagnostic NGS panel. Further analysis by whole exome sequencing needs to be done on a larger cohort, to establish whether additional mutations in other pathways cause resistance to dabrafenib/trametinib.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.